
  <style>
  .gh-table table { 
    border-collapse: collapse; 
    width: 100%;
    border: 1px solid #444;
    font-size: 12px;
  }
  .gh-table th, .gh-table td { 
    border: 1px solid #444; 
    padding: 4px 6px; 
    vertical-align: top;
    font-weight: 400 !important;   /* regular font */
  }
  .gh-table th { 
    .gh-table th { background: #f5f5f5; text-align: left; }
  }
  .gh-table th { font-weight: 700 !important; }
    @media print {
      .gh-table { font-size: 10px; }
    }
  </style>
  <div class='gh-table'><table><thead><tr><th>record_id</th><th>visit</th><th>Molecola (1)</th><th>Molecola (2)</th><th>description</th></tr></thead><tbody><tr><td>L17</td><td>1</td><td>Alendronic acid</td><td>Amiodarone</td><td>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be
increased when Alendronic acid is combined with Amiodarone.</td></tr><tr><td>L17</td><td>1</td><td>Amlodipine</td><td>Amiodarone</td><td>The metabolism of Amlodipine can be decreased when combined with Amiodarone.</td></tr><tr><td>L17</td><td>1</td><td>Apixaban</td><td>Amiodarone</td><td>The metabolism of Apixaban can be decreased when combined with Amiodarone.</td></tr><tr><td>L17</td><td>1</td><td>Apixaban</td><td>Amlodipine</td><td>The metabolism of Apixaban can be decreased when combined with Amlodipine.</td></tr><tr><td>L17</td><td>1</td><td>Doravirine</td><td>Amiodarone</td><td>The metabolism of Doravirine can be decreased when combined with Amiodarone.</td></tr><tr><td>L17</td><td>1</td><td>Doravirine</td><td>Apixaban</td><td>The metabolism of Doravirine can be decreased when combined with Apixaban.</td></tr><tr><td>L17</td><td>1</td><td>Doravirine</td><td>Triazolam</td><td>The metabolism of Doravirine can be decreased when combined with Triazolam.</td></tr><tr><td>L17</td><td>1</td><td>Irbesartan</td><td>Amiodarone</td><td>The serum concentration of Amiodarone can be increased when it is combined with
Irbesartan.</td></tr><tr><td>L17</td><td>1</td><td>Irbesartan</td><td>Apixaban</td><td>The metabolism of Apixaban can be decreased when combined with Irbesartan.</td></tr><tr><td>L17</td><td>1</td><td>Irbesartan</td><td>Tenofovir alafenamide</td><td>The metabolism of Tenofovir alafenamide can be decreased when combined with
Irbesartan.</td></tr><tr><td>L17</td><td>1</td><td>Potassium chloride</td><td>Amiodarone</td><td>Potassium chloride may increase the hyperkalemic activities of Amiodarone.</td></tr><tr><td>L17</td><td>1</td><td>Potassium chloride</td><td>Amlodipine</td><td>Potassium chloride may increase the hyperkalemic activities of Amlodipine.</td></tr><tr><td>L17</td><td>1</td><td>Potassium chloride</td><td>Irbesartan</td><td>Potassium chloride may increase the hyperkalemic activities of Irbesartan.</td></tr><tr><td>L17</td><td>1</td><td>Potassium chloride</td><td>Tenofovir alafenamide</td><td>The serum concentration of Tenofovir alafenamide can be increased when it is
combined with Potassium chloride.</td></tr><tr><td>L17</td><td>1</td><td>Potassium chloride</td><td>Triazolam</td><td>Potassium chloride may decrease the excretion rate of Triazolam which could
result in a higher serum level.</td></tr><tr><td>L17</td><td>1</td><td>Rosuvastatin</td><td>Alendronic acid</td><td>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be
increased when Alendronic acid is combined with Rosuvastatin.</td></tr><tr><td>L17</td><td>1</td><td>Rosuvastatin</td><td>Amiodarone</td><td>The metabolism of Rosuvastatin can be increased when combined with Amiodarone.</td></tr><tr><td>L17</td><td>1</td><td>Rosuvastatin</td><td>Apixaban</td><td>The metabolism of Apixaban can be decreased when combined with Rosuvastatin.</td></tr><tr><td>L17</td><td>1</td><td>Rosuvastatin</td><td>Irbesartan</td><td>The metabolism of Rosuvastatin can be decreased when combined with Irbesartan.</td></tr><tr><td>L17</td><td>1</td><td>Rosuvastatin</td><td>Tenofovir alafenamide</td><td>The excretion of Tenofovir alafenamide can be decreased when combined with
Rosuvastatin.</td></tr><tr><td>L17</td><td>1</td><td>Rosuvastatin</td><td>Triazolam</td><td>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be
increased when Triazolam is combined with Rosuvastatin.</td></tr><tr><td>L17</td><td>1</td><td>Tenofovir alafenamide</td><td>Alendronic acid</td><td>The risk or severity of nephrotoxicity and hypocalcemia can be increased when
Tenofovir alafenamide is combined with Alendronic acid.</td></tr><tr><td>L17</td><td>1</td><td>Tenofovir alafenamide</td><td>Amiodarone</td><td>The serum concentration of Tenofovir alafenamide can be increased when it is
combined with Amiodarone.</td></tr><tr><td>L17</td><td>1</td><td>Tenofovir alafenamide</td><td>Amlodipine</td><td>The metabolism of Tenofovir alafenamide can be decreased when combined with
Amlodipine.</td></tr><tr><td>L17</td><td>1</td><td>Triazolam</td><td>Alendronic acid</td><td>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be
increased when Alendronic acid is combined with Triazolam.</td></tr><tr><td>L17</td><td>1</td><td>Triazolam</td><td>Amiodarone</td><td>The metabolism of Triazolam can be decreased when combined with Amiodarone.</td></tr><tr><td>L17</td><td>1</td><td>Triazolam</td><td>Apixaban</td><td>The metabolism of Apixaban can be decreased when combined with Triazolam.</td></tr><tr><td>L17</td><td>1</td><td>Triazolam</td><td>Tenofovir alafenamide</td><td>The serum concentration of Tenofovir alafenamide can be increased when it is
combined with Triazolam.</td></tr></tbody></table></div>
